Peptides can offer the versatility needed for a successful oncology drug discovery approach.
Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present …

Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting
ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates …

Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …

Cancer became recently the leading cause of death in industrialized countries. Even though
standard treatments achieve significant effects in growth inhibition and tumor elimination …

Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

Nanomaterial-based phototherapy has become an important research direction for cancer
therapy, but it still to face some obstacles, such as the toxic side effects and low target …

Peptides are increasingly being developed for use as therapeutics to treat many ailments,
including cancer. Therapeutic peptides have the advantages of target specificity and low …

Functional nanomaterials as nanodrugs based on the self‐assembly of inorganics,
polymers, and biomolecules have showed wide applications in biomedicine and tissue …